Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]
A new-generation antimuscarinic agent, solifenacin succinate (Vesicare®; Astellas Pharma Co. Ltd, Tokyo, Japan), is a once-daily oral agent that shows apparent functional selectivity for the bladder over other organs in animal models (6).
solifenacin succinate is a once-daily, oral antimusarinic agent, which shows in vitro selectivity for bladder tissue over salivary preparations (7,8).